Anaptysbio, IncANAB

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$51.00
Market cap
$1.5B
P/E
7.7x
Revenue (TTM)
$237.6M
Net income
$195.7M
Dividend yield
—
1-year total return
247.1%
Net margin
82.4%
Revenue growth
92.9%
Debt / equity
—

What Anaptysbio, Inc does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$75.0M$63.2M$10.3M$17.2M$91.3M$234.6M
Net income-$19.9M-$57.8M-$128.7M-$163.6M-$145.2M-$13.2M
Free cash flow-$14.7M-$47.3M-$74.0M-$121.6M-$135.7M$19.6M

More on ANAB.

Figures from Anaptysbio, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.